173 related articles for article (PubMed ID: 32474505)
1. Induction chemotherapy for unresectable Stage III non-small-cell lung cancer may improve survival of induction chemotherapy responders as predicted by elevated levels of carcinoembryonic antigen and cytokeratin fragment 19 and classification as stage N3 cancer.
Li Q; Jiang M; Han X; Yang Z; Shu W; Ding X
J Cancer Res Ther; 2020; 16(2):222-229. PubMed ID: 32474505
[TBL] [Abstract][Full Text] [Related]
2. The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer.
Zhao T; Mao G; Chen M
Comput Math Methods Med; 2021; 2021():1951364. PubMed ID: 34603482
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of CYFRA21-1, CEA and hemoglobin in patients with esophageal squamous cancer undergoing concurrent chemoradiotherapy.
Zhang HQ; Wang RB; Yan HJ; Zhao W; Zhu KL; Jiang SM; Hu XG; Yu JM
Asian Pac J Cancer Prev; 2012; 13(1):199-203. PubMed ID: 22502668
[TBL] [Abstract][Full Text] [Related]
4. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
5. Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.
Fournel P; Vergnenégre A; Robinet G; Léna H; Gervais R; Le Caer H; Souquet PJ; Chavaillon JM; Bozonnat MC; Daurès JP; Chouaid C; Martel-Lafay I;
Eur J Cancer; 2016 Jan; 52():181-7. PubMed ID: 26689864
[TBL] [Abstract][Full Text] [Related]
6. Combined detection of estrogen and tumor markers is an important reference factor in the diagnosis and prognosis of lung cancer.
Bai Y; Shen W; Zhu M; Zhang L; Wei Y; Tang H; Zhao J
J Cell Biochem; 2019 Jan; 120(1):105-114. PubMed ID: 30216488
[TBL] [Abstract][Full Text] [Related]
7. CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study.
Zhao T; Jin Y; Mao G; Wei Y; Wu G; Ye X; Zhou Y; Yuan G; Gao L; Hong Y; Chen Y; Hong C; Zhou H; Su D; Qin Z; Lu L
Medicine (Baltimore); 2016 Dec; 95(52):e5748. PubMed ID: 28033287
[TBL] [Abstract][Full Text] [Related]
8. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
[TBL] [Abstract][Full Text] [Related]
9. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
[TBL] [Abstract][Full Text] [Related]
10. CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.
Sone K; Oguri T; Nakao M; Kagawa Y; Kurowaka R; Furuta H; Fukuda S; Uemura T; Takakuwa O; Kanemitsu Y; Ohkubo H; Takemura M; Maeno K; Ito Y; Sato H; Muramatsu H; Niimi A
Anticancer Res; 2017 Feb; 37(2):935-939. PubMed ID: 28179355
[TBL] [Abstract][Full Text] [Related]
11. [Variations in Serum CEA and CYFRA21-1 Levels Before and After Surgery Facilitate Prognosis of Non-small Cell Lung Cancer Patients].
Duan X; Cui Y; Gong M; Tian F; Shi G; Wu B; Liu M; Guo J; Kong Y
Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):358-64. PubMed ID: 26104892
[TBL] [Abstract][Full Text] [Related]
12. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
14. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M
Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105.
Salama JK; Stinchcombe TE; Gu L; Wang X; Morano K; Bogart JA; Crawford JC; Socinski MA; Blackstock AW; Vokes EE;
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e269-74. PubMed ID: 21477940
[TBL] [Abstract][Full Text] [Related]
16. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
[TBL] [Abstract][Full Text] [Related]
17. [Clinical value of CEA and CYFRA21-1 as an assessment indicator of therapeutic efficacy in advanced non-small cell lung cancer patients].
Li L; Song LH; Ding SC; Zhang XJ; Qiang L; Han CY; Yuan XT; Xu DD
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):850-4. PubMed ID: 21223692
[TBL] [Abstract][Full Text] [Related]
18. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
Hang ZQ; Zheng MF; Huang JH
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325).
Dehing-Oberije C; Aerts H; Yu S; De Ruysscher D; Menheere P; Hilvo M; van der Weide H; Rao B; Lambin P
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):360-8. PubMed ID: 20888135
[TBL] [Abstract][Full Text] [Related]
20. Decline of serum CYFRA21-1 during chemoradiotherapy of NSCLC: a probable predictive factor for tumor response.
Wang J; Zhang N; Li B; Wang Z; Sun H; Yi Y; Huang W
Tumour Biol; 2011 Aug; 32(4):689-95. PubMed ID: 21409421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
